We Manufacture Products That Change Lives™

Life changing perinatal tissue allografts based on our proprietary BioREtain® process.

ABOUT US

Best-In-Class Perinatal Tissue Allografts

  • BioStem Technologies® produces innovative perinatal tissue-based allografts.
  • Our membrane allografts are manufactured using our proprietary BioREtain® processing method that preserves the quality of the tissue.
  • In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
ABOUT US

Best-In-Class Perinatal Tissue Allografts

  • BioStem Technologies® produces innovative perinatal tissue-based allografts.
  • Our membrane allografts are processed using our proprietary BioREtain® processing method that preserves the biologic quality of the tissue.
  • In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Working with us

Why Choose Us

Who We Are

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.

Why BioStem

Our allografts are processed utilizing our proprietary BioREtain® method, which focuses on preserving the tissue’s endogenous biological properties while maintaining the structure and matrix found in fresh perinatal tissue.

Our Goal

BioStem is committed to improving patients’ quality of life through scientific innovation and strict adherence to our quality system.

How We Help

Latest News

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes

The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes July 17, 2025 07:00 ET | Source: BioStem Technologies, Inc. POMPANO BEACH, Fla., July 17, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the Centers for Medicare…

Stay In Touch

Subscribe To Our Newsletter

To stay up to date on all of our news, products, and achievements, please subscribe to our newsletter.

Our Social Media: